Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire New Injectable Medicine Manufacturing Facility of Nexus Pharmaceuticals, Inc. on April 22, 2024. As part of the transaction, Weil, Gotshal & Manges LLP is acting as legal advisor to Eli Lilly and Company. Centerview Partners LLC is acting as financial advisor, and Sullivan & Cromwell LLP as legal advisor to Nexus Pharmaceuticals, Inc.
Market Closed -
Other stock markets
|
Pre-market 08:14:04 am | |||
775 USD | -0.36% | 777.8 | +0.36% |
May. 08 | China Merchants Initiates Eli Lilly at Buy Rating With $852 Price Target | MT |
May. 07 | Coca Cola's new bond prices tight, investors still hungry for new debt | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.95% | 698B | |
+26.51% | 568B | |
-4.97% | 358B | |
+18.83% | 328B | |
+3.54% | 283B | |
+16.00% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+6.70% | 165B | |
-1.81% | 160B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly and Company entered into a definitive agreement to acquire New Injectable Medicine Manufacturing Facility of Nexus Pharmaceuticals, Inc.